Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Ascendis Pharma Yönetim

Yönetim kriter kontrolleri 2/4

Ascendis Pharma's CEO'su Jan Mikkelsen, Dec2007 tarihinde atandı, in görev süresi 16.83 yıldır. şirketin hisselerinin 0.71% doğrudan sahiptir ve bu hisselerin değeri € 57.09M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 8.2 yıl ve 6.7 yıldır.

Anahtar bilgiler

Jan Mikkelsen

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	16.8yrs
CEO sahipliği	0.7%
Yönetim ortalama görev süresi	8.2yrs
Yönetim Kurulu ortalama görev süresi	6.7yrs

Son yönetim güncellemeleri

Recent updates

CEO

Jan Mikkelsen (64 yo)

16.8yrs

Görev süresi

Mr. Jan Moller Mikkelsen serves as the Chief Executive Officer, President, Executive Director and Member of Executive Board of Ascendis Pharma A/S since December 2007. He is Director at Eyconis, Inc. He se...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jan Mikkelsen	President	16.8yrs	Veri yok	0.71% € 49.4m
Scott Smith	CFO, Executive VP & Member of Executive Board	8.2yrs	Veri yok	0.0067% € 468.2k
Lotte Sonderbjerg	Executive VP	16.8yrs	Veri yok	0.0031% € 216.7k
Michael Jensen	Executive VP	11.3yrs	Veri yok	0.0032% € 225.1k
Mads Bodenhoff	Senior VP of Finance & Principal Accounting Officer	less than a year	Veri yok	Veri yok
Timothy Lee	Senior Director of Investor Relations	no data	Veri yok	Veri yok
Flemming Jensen	Executive Vice President of Product Supply & Quality	9.2yrs	Veri yok	0.0031% € 216.7k
Kennett Sprogoe	Executive VP and Head of Research & Product Development	8.8yrs	Veri yok	0.0048% € 336.5k
Stina Singel	Executive VP & Head of Clinical Development for Oncology	2.8yrs	Veri yok	Veri yok
Joseph Kelly	Head of U.S. Commercial of Endocrinology	2.4yrs	Veri yok	Veri yok
Scott Holmes	Head of Global Commercial Strategy of Endocrinology	2.4yrs	Veri yok	Veri yok
Camilla Hartvig	Executive VP & Global Chief Commercial Officer	1.3yrs	Veri yok	Veri yok

8.2yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: A71 'un yönetim ekibi deneyimli ve deneyimlidir ( 8.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jan Mikkelsen	President	16.8yrs	Veri yok	0.71% € 49.4m
Albert Cha	Independent Chairman	9.9yrs	€139.72k	0.00065% € 45.3k
William Fairey	Independent Director	2.1yrs	€73.01k	0% € 0
Lisa Morrison	Independent Director	7.5yrs	€92.64k	0.00065% € 45.3k
Lars Holtug	Independent Director	5.9yrs	€96.17k	0.0015% € 103.8k
Siham Imani	Independent Director	2.1yrs	€69.48k	0% € 0

6.7yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: A71 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.7 yıldır).

Ascendis Pharma Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Ascendis Pharma A/S, Annual General Meeting, May 30, 2024

Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer

Ascendis Pharma A/S, Annual General Meeting, May 30, 2023

Ascendis Pharma A/S Appoints William Carl Fairey Jr. and Siham Imani as Class I Directors

Ascendis Pharma A/S, Annual General Meeting, May 30, 2022

Ascendis Pharma A/S Announces Michael Wolf Jensen Does Not Stand for Re-Election to Its Board

Recent updates

Ascendis Pharma A/S Announces Submission of Supplemental Biologics License Application to FDA for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency

Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $300 million.

Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $300 million.

Ascendis Pharma A/S Announces Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (Proc) Cohort of the Phase 1/2 Il-Believe Trial At Esmo 2024

New minor risk - Share price stability

Second quarter 2024 earnings released: €1.91 loss per share (vs €2.16 loss in 2Q 2023)

Ascendis Pharma A/S to Report Q2, 2024 Results on Sep 03, 2024

Ascendis Pharma A/S Announces Food & Drug Administration Approves Yorvipath® (Palopegteriparatide; Developed as Transcon Pth) for the Treatment of Hypoparathyroidism in Adults

Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism

New minor risk - Shareholder dilution

Ascendis Pharma A/S Announces 2-Year Results from A Post-Hoc Analysis of the Company's Phase 3 PaTHway Trial

First quarter 2024 earnings released: €2.30 loss per share (vs €1.98 loss in 1Q 2023)

Ascendis Pharma A/S, Annual General Meeting, May 30, 2024

Ascendis Pharma A/S to Report Q1, 2024 Results on May 02, 2024

Ascendis Pharma A/S Announces United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer

Full year 2023 earnings released: €8.55 loss per share (vs €10.40 loss in FY 2022)

Ascendis Pharma A/S to Report Fiscal Year 2023 Results on Feb 07, 2024

Ascendis Pharma A/S Introduces Vision 2030

New minor risk - Profitability

Ascendis Pharma A/S Announces New Analyses from Blinded and Ongoing Open-Label Extension Portions of ACcomplisH

Ascarma A/S Announces TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

FDA Accepts for Review Resubmitted NDA for Transcon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism

Ascendis Pharma A/S Announces European Commission Approval of YORVIPATH (Palopegteriparatide) for Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Resubmits NDA for TransCon™? PTH to the U.S. FDA

New minor risk - Profitability

New major risk - Negative shareholders equity

New major risk - Negative shareholders equity

Third quarter 2023 earnings released: €2.88 loss per share (vs €3.03 loss in 3Q 2022)

Ascendis Presents Updated and New Transco Il-2 ß/? Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types At Esmo 2023

Ascendis Pharma A/S Presents Transcon Pth Data At the American Thyroid Association Annual Meeting

Ascendis Pharma A/S Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency

Ascendis Pharma Launches SKYTROFA (Lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

Ascendis Pharma A/S Receives Positive CHMP Opinion for Transcon PTH (Palopegteriparatide) for Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Announces New Post Hoc Analysis Showing Adults with Hypoparathyroidism Treated with TransCon PTH

Ascendis Pharma A/S to Report Q2, 2023 Results on Sep 05, 2023

Aendis Pharma A/S Reports One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

Ascendis Pharma Showcases its Latest Endocrinology Programs, Data, and Research at ENDO 2023

Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates

Ascendis Pharma A/S, Annual General Meeting, May 30, 2023

Full year 2022 earnings released: €10.40 loss per share (vs €7.00 loss in FY 2021)

Ascendis Pharma A/S to Report Fiscal Year 2022 Results on Feb 16, 2023

Ascendis Pharma A/S Announces U.S. Food & Drug Administration Allows to Initiate an Expanded Access Program for Its Investigational Parathyroid Hormone Replacement Therapy, Transcon PTH

Ascendis Pharma Submits Marketing Authorization Application to the European Medicines Agency for Transcon™ PTH in Adult Patients with Hypoparathyroidism

TransCon CNP Achieves Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years

Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022

Third quarter 2022 earnings released: €3.03 loss per share (vs €1.47 loss in 3Q 2021)

Ascendis Pharma A/S Announces FDA Accepts for Priority Review Its NDA for TransCon(TM) PTH in Adult Patients with Hypoparathyroidism

Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for TranscendIT-101, A Phase 1/2 Clinical Trial of TransCon TLR7/8 Agonist in Solid Tumors

Ascendis Pharma A/S Appoints William Carl Fairey Jr. and Siham Imani as Class I Directors

Ascendis Pharma A/S announces new Week 110 data from the Phase 2 PaTH Forward Trial

Ascendis Pharma Submits Transcon™ Pth New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism

Second quarter 2022 earnings released: €1.46 loss per share (vs €2.50 loss in 2Q 2021)

Ascendis Pharma A/S Announces Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon HGH in China Consistent

First quarter 2022 earnings released: €2.21 loss per share (vs €1.17 loss in 1Q 2021)

Ascendis Pharma A/S, Annual General Meeting, May 30, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency

Ascendis Pharma A/S to Provide an Update on Two of Its Investigational Endocrinology Rare Disease Development Programs

Third quarter 2021 earnings released: €1.47 loss per share (vs €2.31 loss in 3Q 2020)

Ascendis Pharma A/S Announces Mean Bone Mineral Density Data from Phase 2 PaTH Forward Trial Demonstrating Continued Normalization and Stabilization of BMD Z-scores Between 26 and 58 Weeks

Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ IL-2 ß/? Clinical Program

Ascendis Pharma Announces U.S. Food and Drug Administration Approval of SKYTROFA

Second quarter 2021 earnings released: €2.50 loss per share (vs €1.97 loss in 2Q 2020)

Ascendis Pharma A/S Announces U.S. Food and Drug Administration Notifies Information Submitted in Connection with the FDA's Ongoing Review of the Biologics License Application for Lonapegsomatropin

VISEN Pharmaceuticals Obtains the Investigational New Drug Approval from the Center for Drug Evaluation of the National Medical Products Administration for the Phase III China Clinical Trial of TransCon Parathyroid Hormone

First quarter 2021 earnings released: €1.17 loss per share (vs €1.32 loss in 1Q 2020)